Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Khandelwal, Preeti J ^a   Dumanis, Sonya B ^a   Feng, Li Rebekah ^a   Maguire Zeiss, Kathleen ^a   Rebeck, Gw ^a   Lashuel, Hilal A ^b   Moussa, Charbel Eh ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; LENTIVIRUS VECTOR; PARKIN; PHOSPHOPROTEIN PHOSPHATASE 2A; POLO LIKE KINASE 2; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE INTERACTION; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; INFLAMMATION; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RAT; VIRAL GENE DELIVERY SYSTEM; VIRUS EXPRESSION; WILD TYPE;

ANIMALIA; RATTUS;

EID: 78049368074     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-47     Document Type: Article

References (50)

1. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. M Goedert, Philos Trans R Soc Lond B Biol Sci 1999 354 1101 1118 10.1098/rstb.1999.0466 10434313
2. Alpha-synuclein and neurodegenerative diseases. M Goedert, Nat Rev Neurosci 2001 2 492 501 10.1038/35081564 11433374
3. Pathogenic effects of alpha-synuclein aggregation. D Lundvig E Lindersson PH Jensen, Brain Res Mol Brain Res 2005 134 3 17 10.1016/j.molbrainres.2004.09. 001 15790525
4. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. MG Spillantini RA Crowther R Jakes NJ Cairns PL Lantos M Goedert, Neurosci Lett 1998 251 205 208 10.1016/S0304-3940(98)00504-7 9726379 (Pubitemid 28381082)
5. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. MG Spillantini RA Crowther R Jakes M Hasegawa M Goedert, Proc Natl Acad Sci USA 1998 95 6469 6473 10.1073/pnas.95.11.6469 9600990 (Pubitemid 28249037)
6. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. MG Spillantini M Goedert, Ann N Y Acad Sci 2000 920 16 27 10.1111/j.1749-6632.2000.tb06900.x 11193145
7. Alpha-synuclein in Lewy bodies. MG Spillantini ML Schmidt VM Lee JQ Trojanowski R Jakes M Goedert, Nature 1997 388 839 840 10.1038/42166 9278044
8. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. A Takeda M Hashimoto M Mallory M Sundsumo L Hansen E Masliah, Acta Neuropathol 2000 99 296 304 10.1007/PL00007441 10663973
9. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. JQ Trojanowski VM Lee, Ann N Y Acad Sci 2003 991 107 110 10.1111/j.1749-6632.2003.tb07468.x 12846979
10. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. K Wakabayashi K Matsumoto K Takayama M Yoshimoto H Takahashi, Neurosci Lett 1997 239 45 48 10.1016/S0304-3940(97)00891-4 9547168
11. alpha-Synuclein is phosphorylated in synucleinopathy lesions. H Fujiwara M Hasegawa N Dohmae A Kawashima E Masliah MS Goldberg J Shen K Takio T Iwatsubo, Nat Cell Biol 2002 4 160 164 10.1038/ncb841 11813001
12. Accumulation of phosphorylated alpha-synuclein in aging human brain. Y Saito A Kawashima NN Ruberu H Fujiwara S Koyama M Sawabe T Arai H Nagura H Yamanouchi M Hasegawa T Iwatsubo S Murayama, J Neuropathol Exp Neurol 2003 62 644 654 12834109
13. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. M Nishie F Mori H Fujiwara M Hasegawa M Yoshimoto T Iwatsubo H Takahashi K Wakabayashi, Acta Neuropathol 2004 107 292 298 10.1007/s00401-003-0811-1 14722716
14. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. M Okochi J Walter A Koyama S Nakajo M Baba T Iwatsubo L Meijer PJ Kahle C Haass, J Biol Chem 2000 275 390 397 10.1074/jbc.275.1.390 10617630
15. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. AN Pronin AJ Morris A Surguchov JL Benovic, J Biol Chem 2000 275 26515 26522 10.1074/jbc.M003542200 10852916
16. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. PJ Kahle M Neumann L Ozmen V Muller H Jacobsen W Spooren B Fuss B Mallon WB Macklin H Fujiwara M Hasegawa T Iwatsubo HA Kretzschmar C Haass, EMBO Rep 2002 3 583 588 10.1093/embo-reports/kvf109 12034752
17. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. M Takahashi H Kanuka H Fujiwara A Koyama M Hasegawa M Miura T Iwatsubo, Neurosci Lett 2003 336 155 158 10.1016/S0304-3940(02)01258-2 12505616
18. Phosphorylation of synucleins by members of the Polo-like kinase family. MK Mbefo KE Paleologou A Boucharaba A Oueslati H Schell M Fournier D Olschewski G Yin M Zweckstetter E Masliah PJ Kahle H Hirling HA Lashuel, J Biol Chem 2010 285 2807 2822 10.1074/jbc.M109.081950 19889641
19. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. T Kitada S Asakawa N Hattori H Matsumine Y Yamamura S Minoshima M Yokochi Y Mizuno N Shimizu, Nature 1998 392 605 608 10.1038/33416 9560156 (Pubitemid 28207717)
20. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. N Hattori H Matsumine S Asakawa T Kitada H Yoshino B Elibol AJ Brookes Y Yamamura T Kobayashi M Wang A Yoritaka S Minoshima N Shimizu Y Mizuno, Biochem Biophys Res Commun 1998 249 754 758 10.1006/bbrc.1998.9134 9731209
21. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. H Mori T Kondo M Yokochi H Matsumine Y Nakagawa-Hattori T Miyake K Suda Y Mizuno, Neurology 1998 51 890 892 9748052
22. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. H Shimura MG Schlossmacher N Hattori MP Frosch A Trockenbacher R Schneider Y Mizuno KS Kosik DJ Selkoe, Science 2001 293 263 269 10.1126/science.1060627 11431533
23. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Y Imai M Soda R Takahashi, J Biol Chem 2000 275 35661 35664 10.1074/jbc.C000447200 10973942
24. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Y Imai M Soda H Inoue N Hattori Y Mizuno R Takahashi, Cell 2001 105 891 902 10.1016/S0092-8674(01)00407- X 11439185
25. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. C Lo Bianco BL Schneider M Bauer A Sajadi A Brice T Iwatsubo P Aebischer, Proc Natl Acad Sci USA 2004 101 17510 17515 10.1073/pnas.0405313101 15576511
26. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. L Petrucelli C O'Farrell PJ Lockhart M Baptista K Kehoe L Vink P Choi B Wolozin M Farrer J Hardy MR Cookson, Neuron 2002 36 1007 1019 10.1016/S0896-6273(02)01125-X 12495618
27. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. AJ Whitworth DA Theodore JC Greene H Benes PD Wes LJ Pallanck, Proc Natl Acad Sci USA 2005 102 8024 8029 10.1073/pnas.0501078102 15911761
28. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. KK Chung Y Zhang KL Lim Y Tanaka H Huang J Gao CA Ross VL Dawson TM Dawson, Nat Med 2001 7 1144 1150 10.1038/nm1001-1144 11590439
29. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. AF Haywood BE Staveley, BMC Neurosci 2004 5 14 10.1186/1471-2202-5-14 15090075
30. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Y Yang I Nishimura Y Imai R Takahashi B Lu, Neuron 2003 37 911 924 10.1016/S0896-6273(03)00143-0 12670421
31. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. JP Anderson DE Walker JM Goldstein R de Laat K Banducci RJ Caccavello R Barbour J Huang K Kling M Lee L Diep PS Keim X Shen T Chataway MG Schlossmacher P Seubert D Schenk S Sinha WP Gai TJ Chilcote, J Biol Chem 2006 281 29739 29752 10.1074/jbc. M600933200 16847063
32. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. DM Sampathu BI Giasson AC Pawlyk JQ Trojanowski VM Lee, Am J Pathol 2003 163 91 100 12819014
33. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. WW Smith RL Margolis X Li JC Troncoso MK Lee VL Dawson TM Dawson T Iwatsubo CA Ross, J Neurosci 2005 25 5544 5552 10.1523/JNEUROSCI.0482-05.2005 15944382
34. Parkin promotes intracellular Abeta1-42 clearance. MP Burns L Zhang GW Rebeck HW Querfurth CE Moussa, Hum Mol Genet 2009 18 3206 3216 10.1093/hmg/ddp258 19483198
35. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. KJ Inglis D Chereau EF Brigham SS Chiou S Schobel NL Frigon M Yu RJ Caccavello S Nelson R Motter S Wright D Chian P Santiago F Soriano C Ramos K Powell JM Goldstein M Babcock T Yednock F Bard GS Basi H Sham TJ Chilcote L McConlogue I Griswold-Prenner JP Anderson, J Biol Chem 2009 284 2598 2602 10.1074/jbc.C800206200 19004816
36. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. P Ibanez AM Bonnet B Debarges E Lohmann F Tison P Pollak Y Agid A Durr A Brice, Lancet 2004 364 1169 1171 10.1016/S0140-6736(04)17104-3 15451225
37. Parkinson's disease and dementia with Lewy bodies: a difference in dose? A Singleton K Gwinn-Hardy, Lancet 2004 364 1105 1107 10.1016/S0140-6736(04) 17117-1 15451205
38. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. AB Singleton, Trends Neurosci 2005 28 416 421 10.1016/j.tins.2005.05.009 15955578
39. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. OS Gorbatyuk S Li LF Sullivan W Chen G Kondrikova FP Manfredsson RJ Mandel N Muzyczka, Proc Natl Acad Sci USA 2008 105 763 768 10.1073/pnas.0711053105 18178617
40. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. E Masliah E Rockenstein I Veinbergs M Mallory M Hashimoto A Takeda Y Sagara A Sisk L Mucke, Science 2000 287 1265 1269 10.1126/science.287.5456.1265 10678833
41. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. TC Frank-Cannon T Tran KA Ruhn TN Martinez J Hong M Marvin M Hartley I Trevino DE O'Brien B Casey MS Goldberg MG Tansey, J Neurosci 2008 28 10825 10834 10.1523/JNEUROSCI.3001-08.2008 18945890
42. Serine/threonine phosphatases: mechanism through structure. Y Shi, Cell 2009 139 468 484 10.1016/j.cell.2009.10.006 19879837
43. Structure of the protein phosphatase 2A holoenzyme. Y Xu Y Xing Y Chen Y Chao Z Lin E Fan JW Yu S Strack PD Jeffrey Y Shi, Cell 2006 127 1239 1251 10.1016/j.cell.2006.11.033 17174897
44. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Y Xu Y Chen P Zhang PD Jeffrey Y Shi, Mol Cell 2008 31 873 885 10.1016/j.molcel.2008.08.006 18922469
45. Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. M Fournier J Vitte J Garrigue D Langui JP Dullin F Saurini N Hanoun F Perez-Diaz F Cornilleau C Joubert H Ardila-Osorio S Traver R Duchateau C Goujet-Zalc K Paleologou HA Lashuel C Haass C Duyckaerts C Cohen-Salmon PJ Kahle M Hamon A Brice O Corti, PLoS One 2009 4 6629 10.1371/journal.pone.0006629 19680561
46. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. R von Coelln B Thomas SA Andrabi KL Lim JM Savitt R Saffary W Stirling K Bruno EJ Hess MK Lee VL Dawson TM Dawson, J Neurosci 2006 26 3685 3696 10.1523/JNEUROSCI.0414-06.2006 16597723
47. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. KE Paleologou A Oueslati G Shakked CC Rospigliosi HY Kim GR Lamberto CO Fernandez A Schmid F Chegini WP Gai D Chiappe M Moniatte BL Schneider P Aebischer D Eliezer M Zweckstetter E Masliah HA Lashuel, J Neurosci 2010 30 3184 3198 10.1523/JNEUROSCI.5922-09.2010 20203178
48. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. M Marjanska GL Curran TM Wengenack PG Henry RL Bliss JF Poduslo CR Jack K Ugurbil M Garwood, Proc Natl Acad Sci USA 2005 102 11906 11910 10.1073/pnas.0505513102 16091461
49. The biochemistry of Parkinson's disease. MR Cookson, Annu Rev Biochem 2005 74 29 52 10.1146/annurev.biochem.74.082803.133400 15952880
50. El-Agnaf OM, Bodles AM, Guthrie DJ, Harriott P, Irvine GB: The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur J Biochem 1998, 258:157-163.